Loading…
Loading…
LSB (LakeShore Biopharma Co., Ltd) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
LSB does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for LSB and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LSB and 80,000+ other tickers.
See exactly how LSB's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LSB and 80,000+ other tickers.
LakeShore Biopharma Co., Ltd is a biopharmaceutical firm focused on the discovery, advancement, manufacturing, and marketing of vaccines and therapeutic biologics. Its primary targets are infectious diseases and various forms of cancer. At the core of its innovation is a proprietary PIKA immunomodulating technology platform, which underpins its product pipeline, featuring a PIKA rabies vaccine, a PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. The company maintains an international presence, conducting operations across China, the United States, Singapore, the United Arab Emirates, and…
LSB Industries is rated Buy with a $13.50 target, leveraging a structural U.S. natural gas cost advantage over European peers. Operational efficiency gains, particularly at the El Dorado plant, and a flexible product mix support margin expansion and resilience against agricultural price swings. The carbon capture project is expected to generate $25–30 million in annual cash flow by 2027, with regulatory and execution risks to monitor.
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB,” “we,” “us,” “our,” or the “Company”) today announced results for the second quarter ended June 30, 2026. Second Quarter 2026 Results and Recent Highlights Net sales of $168.1 million compared to $151.3 million in the second quarter of 2025 Net loss of $6.2 million, inclusive of approximately $28.8 million of turnaround expenses, compared to net income of $3.0 million in the second quarter of 2025, inclusive of approximatel.
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”) (NYSE: LXU), today announced that it will release its financial results for the second quarter ended June 30, 2026 on July 29, 2026 after the close of the stock market.LSB's management will host a conference call on Thursday, July 30, 2026 at 10:00 am ET / 9:00 am CT to discuss these results. Participating in the call will be Chairman & Chief Executive Officer, Mark Behrman, Executive Vice President & Chief Financial Officer, C.
LSB Industries, a top-5 U.S. ammonia producer, and a nitrogen-oriented chemical specialist has outperforming other material peers and the Russell 2000 meaningfully this year. Despite facing 900bps of potential margin expansion this year, LXU trades at a forward EV/EBITDA of 5.15x–5.25x, over 20% below its 5-year average, and a 60% discount to the sector. Margin growth is driven by strong pricing growth, higher-value downstream products, a greater share of cost-plus contracts, and ongoing process improvements.
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB” or “the Company”), today announced that it has reached an agreement with Lapis Carbon Solutions (“Lapis”) that establishes a strategic pathway for LSB to take full ownership of Project Blue, the carbon capture and sequestration (“CCS”) project currently underway at its El Dorado, Arkansas facility (“the Project”). “The opportunity to achieve full ownership of this project is an important strategic step for the Company,” sai.